Clinical features of molecular pathology of solid tumours in childhood

Lancet Oncology

Volumn 6, Issue 6, 2005, Pages 421-430

  Messahel, Boo ^a   Hing, Sandra ^c   Nash, Ruth ^b   Jeffrey, Iona ^b   Pritchard Jones, Kathy ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; CYTOTOXIC AGENT; HYBRID PROTEIN; MOLECULAR MARKER; MYC PROTEIN; MYCN PROTEIN; NEUROTROPIN RECEPTOR 3; PROTEIN P53; RECEPTOR PROTEIN; RETINOBLASTOMA PROTEIN; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; UNCLASSIFIED DRUG; WT1 PROTEIN;

CANCER RISK; CANCER SURVIVAL; CARCINOGENICITY; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIAGNOSTIC ACCURACY; DRUG USE; EWING SARCOMA; FIBROSARCOMA; GENE FUSION; GENETIC RISK; HUMAN; METASTASIS; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NEPHROBLASTOMA; NEUROBLASTOMA; ONCOLOGY; PRIORITY JOURNAL; REVIEW; RHABDOID TUMOR; RHABDOMYOSARCOMA; RISK ASSESSMENT; SOFT TISSUE SARCOMA; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; SYNOVIAL SARCOMA; TREATMENT PLANNING;

CHILD; COMBINED MODALITY THERAPY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PEDIGREE; SURVIVORS;

EID: 19944400145     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70209-6     Document Type: Review

References (77)

1. AG Knudson Jr Mutation and cancer: Statistical study of retinoblastoma Proc Natl Acad Sci USA 681971 20-823
2. ND Hastie The genetics of Wilms' tumor-A case of disrupted development Annu Rev Genet 1994 28 523-58
3. JM Varley Germline TP53 mutations and Li-Fraumeni syndrome Hum Mutat 21 2003 313-320
4. T Kusafuka M Fukuzawa T Oue et al. Mutation analysis of p53 gene in childhood malignant solid tumors J Pediatr Surg 32 1997 1175-1180
5. RL Carter SZ al-Sams R.P. Corbett S Clinton A comparative study of immunohistochemical staining for neuron-specific enolase, protein gene product 9·5 and S-100 protein in neuroblastoma, Ewing's sarcoma and other round cell tumours in children Histopathology 16 1990 461-467.
6. DR Lucas G Bentley ME Dan et al. Ewing sarcoma vs lymphoblastic lymphoma: A comparative immunohistochemical study Am J Clin Pathol 115 2001 11-67
7. F Mitelman Catalog of chromosome aberrations in cancer 1998 John Wiley and Sons Inc New York
8. M Peter E Gilbert O Delatre A multiplex real-time pcr assay for the detection of gene fusions observed in solid tumors Lab Invest 81 2001 905-912
9. BL Ebert TR Golub Genomic approaches to hematologic malignancies Blood 104 2004 923-932.
10. J Khan JS Wei M Ringner et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks Nat Med 7 2001 673-679.
11. M, Wachtel M, Dettling Koscielniak E, et al. Gene expresssion signature identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004;64:5539-45
12. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415: 436-42.
13. Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004; 64: 6883-91.
14. Williams RD, Hing SN, Greer BT, et al. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 2004; 41: 65-79.
15. Chen QR, Bilke S, Wei JS, et al. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCNamplification in neuroblastoma. BMC Genomics 2004; 5: 70.
16. Biondi A, Valsecchi MG, Seriu T, et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukaemia with medium risk features: A case control study of the International BFM study group. Leukaemia 2000; 14: 1939-43.
17. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165-73.
18. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol 2003; 4: 472-80.
19. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group. Cancer 2001; 92: 2699-708.
20. Toffolatti L, Frascella E, Ninfo V, et al. MYCN expression in human rhabdomyosarcoma cell lines and tumour samples. J Pathol 2002; 196: 450-58.
21. Williamson D, Lu YJ, Gordon T, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 2005; 23: 880-88.
22. Brodeur GM. Neuroblastoma: Biological insights into a clinical Nat Rev Cancer 2003; 3: 203-16.
23. Bown NP, Reid MM, Malcolm AJ, et al. Cytogenetic abnormalities of small round cell tumours. Med Pediatr Oncol 1994; 23: 124-29
24. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529-35.
25. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-14.
26. Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000; 22: 197-205.
27. Rubie H, Hartmann O, Michon J, et al, for the Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. J Clin Oncol 1997; 15: 1171-82.
28. Rubie H, Delattre O, Hartmann O, et al, for the Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Eur J Cancer 1997; 33: 1917-22.
29. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 225-30.
30. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 1954-61.
31. Eisenman RN. Deconstructing myc. Genes Dev 2001; 15: 2023-30.
32. Cohn SL, London WB, Huang D, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000; 18: 3604-13
33. Raetz EA, Kim MK, Moos P, et al. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer 2003; 98: 841-53.
34. Ambros IM, Benard J, Boavida M, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 2003; 21: 2077-84.
35. Cheung IY, Lo Piccolo MS, Collins N, et al. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer 2002; 94: 3042-48.
36. Swerts K, De Moerloose B, Dhooge C, et al. Detection of residual neuroblastoma cells in bone marrow: Comparison of flow cytometry with immunocytochemistry. Cytometry 2004; 61B: 9-19
37. Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 2001; 19: 1795-801.
38. Seeger RC, Reynolds CP, Gallego R,et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 2000; 18: 4067-76.
39. Lambooy LH, Gidding CE, van den Heuvel LP, et al. Real-time analysis of tyrosine hydroxylase gene expression: A sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. Clin Cancer Res 2003; 9: 812-19.
40. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-65
41. Sorensen PH, Liu XF, Delattre O, et al. Reverse transcriptase PCR amplification of EWS/FLI-1 fusion transcripts as a diagnostic test for peripheral primitive neuroectodermal tumors of childhood. Diagn Mol Pathol 1993; 2: 147-57.
42. May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993; 13: 7393-98.
43. Zucman J, Melot T, Desmaze C, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993; 12: 4481-87.
44. Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995; 10: 1229-34.
45. Shing DC, McMullan DJ, Roberts P, et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res 2003; 63: 4568-76.
46. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14: 1245-51.
47. de Alava E, Panizo A, Antonescu CR, et al. Association of EWSFLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000; 156: 849-55.
48. Ginsberg JP, de Alava E, Ladanyi M, et al. EWS-FLI1 and EWSERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol 1999; 17: 1809-14.
49. Lin PP, Brody RI, Hamelin AC, et al. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 1999; 59: 1428-32.
50. Maurici D, Perez-Atayde A, Grier HE, et al. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet Cytogenet 1998; 100: 106-10.
51. de Alava E, Antonescu CR, Panizo A, et al. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000; 89: 783-92.
52. Wei G, Antonescu CR, de Alava E, et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 2000; 89: 793-99.
53. Zoubek A, Ladenstein R, Windhager R, et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: A preliminary evaluation. Int J Cancer 1998; 79: 56-60.
54. Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 2003; 21: 85-91.
55. Avigad S, Cohen IJ, Zilberstein J, et al. The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer 2004; 100: 1053-58.
56. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 5: 230-35.
57. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54: 2869-72.
58. Barr FG, Qualman SJ, Macris MH, et al. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 2002; 62: 4704-10
59. Sublett JE, Jeon IS, Shapiro DN. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional ctivator. Oncogene 1995; 11: 545-52.
60. Anderson J, Gordon T, McManus A, et al. Detection of the PAX3- FKHR fusion gene in paediatric rhabdomyosarcoma: A reproducible predictor of outcome? Br J Cancer 2001; 85: 831-35.
61. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol 2002; 20: 2672-79.
62. Kelly KM, Womer RB, Barr FG. Minimal disease detection in patients with alveolar rhabdomyosarcoma using a reverse transcriptase-polymerase chain reaction method. Cancer 1996; 78: 1320-27.
63. Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 2001; 23: 99-104.
64. Singer S, Baldini EH, Demetri GD, et al. Synovial sarcoma: Prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol 1996; 14: 1201-08.
65. Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppelassociated box in human synovial sarcoma. EMBO J 1995; 14: 2333-40.
66. Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338: 153-60.
67. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: A multiinstitutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-40.
68. Panagopoulos I, Mertens F, Isaksson M, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer 2001; 31: 362-72.
69. Nilsson G, Skytting B, Xie Y, et al. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 1999; 59: 3180-84.
70. Ladanyi M, Gerald WL. Specificity of the EWS/WT1 gene fusion for desmoplastic small round cell tumour. J Pathol 1996; 180: 462.
71. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/ INI1 in aggressive paediatric cancer. Nature 1998; 394: 203-06.
72. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999; 59: 74-79.
73. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18: 184-87.
74. Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: Cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 1998; 153: 1451-8.
75. Grundy P, Telzerow P, Moksness J, Breslow NE. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: A preliminary analysis. Med Pediatr Oncol 1996; 27: 429-33.
76. Grundy RG, Pritchard J, Scambler P, Cowell JK. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. Br J Cancer 1998; 78: 1181-87.
77. Klamt B, Schulze M, Thate C, et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer 1998; 22: 287-94.